JP2021522793A5 - - Google Patents
Info
- Publication number
- JP2021522793A5 JP2021522793A5 JP2020561726A JP2020561726A JP2021522793A5 JP 2021522793 A5 JP2021522793 A5 JP 2021522793A5 JP 2020561726 A JP2020561726 A JP 2020561726A JP 2020561726 A JP2020561726 A JP 2020561726A JP 2021522793 A5 JP2021522793 A5 JP 2021522793A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- acid sequence
- item
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666547P | 2018-05-03 | 2018-05-03 | |
| US62/666,547 | 2018-05-03 | ||
| US201862779998P | 2018-12-14 | 2018-12-14 | |
| US62/779,998 | 2018-12-14 | ||
| PCT/US2019/030469 WO2019213442A1 (en) | 2018-05-03 | 2019-05-02 | MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522793A JP2021522793A (ja) | 2021-09-02 |
| JP2021522793A5 true JP2021522793A5 (enExample) | 2022-05-13 |
Family
ID=68386158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561726A Pending JP2021522793A (ja) | 2018-05-03 | 2019-05-02 | ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12103959B2 (enExample) |
| EP (1) | EP3788066A4 (enExample) |
| JP (1) | JP2021522793A (enExample) |
| AU (1) | AU2019262139A1 (enExample) |
| CA (1) | CA3099527A1 (enExample) |
| WO (1) | WO2019213442A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021119136A1 (en) * | 2019-12-10 | 2021-06-17 | Acceleron Pharma Inc. | Single-arm actriia and actriib heteromultimers and methods for treating pulmonary hypertension |
| CA3196443A1 (en) * | 2020-11-04 | 2022-05-12 | Hq Han | Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereof |
| US20240277807A1 (en) * | 2021-06-11 | 2024-08-22 | Acceleron Pharma Inc. | Actrii proteins and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| JP6631865B2 (ja) * | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| US10358476B2 (en) | 2015-04-06 | 2019-07-23 | Acceleron Pharma Inc. | Single arm type I and type II receptor fusion proteins and uses thereof |
| MA41920B1 (fr) * | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
| CA3029890A1 (en) | 2016-07-07 | 2018-01-11 | Acceleron Pharma Inc. | Tgf-beta superfamily heteromultimers and uses thereof |
| AU2017338915B2 (en) * | 2016-10-05 | 2024-11-21 | Acceleron Pharma Inc. | TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof |
| CN110036025B (zh) | 2016-10-05 | 2024-03-22 | 阿塞勒隆制药公司 | 变体ActRIIB蛋白及其用途 |
| CN206301918U (zh) * | 2016-12-23 | 2017-07-04 | 深圳国人通信股份有限公司 | 一种介质移相器 |
| US12168683B2 (en) | 2018-05-03 | 2024-12-17 | Acceleron Pharma Inc. | Binders of TGFβ-superfamily ligands and uses thereof |
| CA3103427A1 (en) | 2018-06-15 | 2019-12-19 | Acceleron Pharma Inc. | Bi-and tri-functional fusion proteins and uses thereof |
-
2019
- 2019-05-02 US US17/052,785 patent/US12103959B2/en active Active
- 2019-05-02 JP JP2020561726A patent/JP2021522793A/ja active Pending
- 2019-05-02 CA CA3099527A patent/CA3099527A1/en active Pending
- 2019-05-02 EP EP19796599.9A patent/EP3788066A4/en active Pending
- 2019-05-02 WO PCT/US2019/030469 patent/WO2019213442A1/en not_active Ceased
- 2019-05-02 AU AU2019262139A patent/AU2019262139A1/en not_active Abandoned
-
2024
- 2024-08-21 US US18/811,531 patent/US20250109179A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11918647B2 (en) | TfR selective binding compounds and related methods | |
| JP2021522795A5 (enExample) | ||
| JP6809789B2 (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| JP2022523524A5 (enExample) | ||
| US20230348565A1 (en) | Methods of using activin receptor type ii variants | |
| JP2021175391A5 (enExample) | ||
| US20220177597A1 (en) | Anti-CD98hc VNARs for Crossing the Blood Brain Barrier and Type IV VNAR Libraries | |
| EA032727B1 (ru) | Мутантный резистентный к протеолизу полипептид fgf21 и его применение | |
| JP2021522793A5 (enExample) | ||
| CN106687478A (zh) | 新的抗人Tie‑2抗体 | |
| JP7793774B2 (ja) | メソテリン結合タンパク質及びその使用 | |
| JP2023522799A5 (enExample) | ||
| US20180280474A1 (en) | Treatment of bile acid disorders | |
| JP2020500511A5 (enExample) | ||
| JP2022540918A5 (enExample) | ||
| JP2025116068A (ja) | 腎臓活性融合タンパク質及びそれを使用する治療方法 | |
| JP2025527160A (ja) | 多重特異性抗体およびその使用 | |
| CN117295758A (zh) | 包含抗原结合结构域及细胞因子三聚体结构域的融合蛋白 | |
| JP7829127B2 (ja) | 抗原結合ドメインおよびサイトカイン三量体ドメインを含む融合タンパク質 | |
| JP2024537397A5 (enExample) | ||
| JP2025524899A (ja) | メソテリン結合タンパク質及びその使用 | |
| JP2024537234A5 (enExample) | ||
| TW202342551A (zh) | 包含抗原結合結構域及細胞因數三聚體結構域的融合蛋白 | |
| WO2025228408A1 (zh) | Ghr激动型抗体及其应用 | |
| CN118119402A (zh) | 工程化抗her2双特异性蛋白 |